Evonik, one of the world's leading providers of drug delivery technologies, is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the United States, said the company.
The new plant at Evonik’s Tippecanoe site in Lafayette, Indiana, will broadly position the Group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines and strengthen its leading role as a strategic partner for innovative pharmaceutical companies worldwide. Construction will begin in early 2023, and the plant is scheduled to goon stream in 2025. The investment into the lipid facility will help create more than 80 highly skilled jobs in the Lafayette region.
The total investment amounts to USD220 million. The U.S. Government is funding the facility with up to US$150 million through its Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. BARDA promotes the advanced development of medical countermeasures to respond to 21st century health security threats and coordinated contracting support with the support of the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). Additional support will be provided by the Indiana Economic Development Corporation (IEDC), Greater Lafayette Commerce (GLC), and Duke Energy.
The Health Care business of Evonik, a specialty chemicals company headquartered in Essen, Germany, serves as a leading and integrated service provider of products and technologies for mRNA-based medicines. Evonik has been supplying major pharmaceutical companies worldwide with the lipids needed for use with mRNA active ingredients (messenger ribonucleic acid). Lipids are critical components in the formulation of nucleic acid therapies.
During the coronavirus pandemic, Evonik made a crucial contribution by providing lipids to the Pfizer/BioNTech COVID-19 vaccine and vaccination campaigns worldwide. mRNA serves as a carrier of genetic information in cells. It can be designed for a broad range of pharmacological applications. mRNA vaccines, for example, teach cells how to make a protein that will trigger an immune response.
As per MRC, Evonik, one the world's petrochemical majors, is embarking on the next phase of its strategic transformation. Sustainability is being integrated fully and systematically into all elements of the strategy: portfolio management, innovation, corporate culture.
We remind that in February, 2020, Dow and Evonik entered into an exclusive technology partnership. Together, they plan to bring a unique method for directly synthesizing propylene glycol (PG) from propylene and hydrogen peroxide to market maturity.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of EUR12.2 billion and an operating profit (adjusted EBITDA) of EUR1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: to improve life today and tomorrow.
mrchub.com